PIK3CA mutation	HER2 Negative Breast Cancer	PIK3CA mutation	HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B	neratinib Resistant: B - Late Trials neratinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B	trastuzumab Resistant: B - Late Trials trastuzumab Resistant : B
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B	trastuzumab + pertuzumab + alpelisib Sensitive: B - Late Trials trastuzumab + pertuzumab + alpelisib Sensitive : B
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	ado-trastuzumab emtansine + pertuzumab Resistant: B - Late Trials ado-trastuzumab emtansine + pertuzumab Resistant : B	ado-trastuzumab emtansine + pertuzumab Resistant: B - Late Trials ado-trastuzumab emtansine + pertuzumab Resistant : B
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2
PIK3CA mutation	Uterine Cancer	PIK3CA mutation	Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2	palbociclib Sensitive: C2 – Inclusion Criteria palbociclib Sensitive : C2
PIK3CA mutation	Ovarian Cancer	PIK3CA mutation	Ovarian Cancer	CYH33 Sensitive: C2 – Inclusion Criteria CYH33 Sensitive : C2	CYH33 Sensitive: C2 – Inclusion Criteria CYH33 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	AZD5363 Sensitive: C2 – Inclusion Criteria AZD5363 Sensitive : C2	AZD5363 Sensitive: C2 – Inclusion Criteria AZD5363 Sensitive : C2
PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Hormone Receptor Positive Breast Cancer	PIK3CA mutation	Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	ARQ 751 Sensitive: C2 – Inclusion Criteria ARQ 751 Sensitive : C2	ARQ 751 Sensitive: C2 – Inclusion Criteria ARQ 751 Sensitive : C2
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	temsirolimus Sensitive: C2 – Inclusion Criteria temsirolimus Sensitive : C2	temsirolimus Sensitive: C2 – Inclusion Criteria temsirolimus Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + alpelisib Sensitive: C2 – Inclusion Criteria trastuzumab + alpelisib Sensitive : C2	trastuzumab + alpelisib Sensitive: C2 – Inclusion Criteria trastuzumab + alpelisib Sensitive : C2
PIK3CA mutation	Non Small Cell Lung Cancer	PIK3CA mutation	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PIK3CA mutation	Urothelial Cancer	PIK3CA mutation	Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3

PIK3CA mutation

Associations